Volanesorsen · Waylivra

RNA / oligonucleotide

Also known as ISIS 304801

Approvedregulatory verdict

Evidence outlook

Approved: Waylivra (PTC Therapeutics): familial chylomicronemia syndrome (FCS) (BR)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also in development:Severe Hypertriglyceridemia · Phase 3 · investigational in the US

Also approved (2)
BR
  • Waylivra (PTC Therapeutics): familial chylomicronemia syndrome (FCS)
Product first approved 2021prnewswire.com
EU
  • Genetically confirmed familial chylomicronemia syndrome at high risk of pancreatitis (conditional)
Product first approved 2019EMA

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Familial Chylomicronemia Syndrome
NCT02658175 · Akcea Therapeutics
2015-12-23 – 2020-01-15 · Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
What this study did
Other / comorbidity
Phase 2/3 (1)
Other / comorbidity
NCT02527343 · Akcea Therapeutics
2015-12-28 – 2019-11-13 · Familial Partial Lipodystrophy
What this study did
Phase 2 (1)
Other / comorbidity
NCT02639286 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2015-12-23 – 2019-09-26 · Lipodystrophy
What this study did
Phase 1 (1)
Other / comorbidity
NCT02910635 · Ionis Pharmaceuticals, Inc.
2016-09-19 – 2016-12-20 · Abnormalities, Cardiovascular
What this study did

Competitive landscape

This drug's own stage for Familial Chylomicronemia Syndrome: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Volanesorsen (Waylivra): this drugPhase 3RNA / oligonucleotideAPOC3 mRNAReliable signal
NCT02211209: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Placebo 17.6 percent change (95% CI -4 to 39.2) | Volanesorsen -76.5 percent change (95% CI -97.4 to -55.5)
Olezarsen (Tryngolza)ApprovedRNA / oligonucleotideAPOC3Partial signal
NCT04568434: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53.
Plozasiran (Redemplo)ApprovedRNA / oligonucleotideAPOC3Partial signal
NCT05089084: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47)
CS-121Phase 1Gene therapy / editingAPOC3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.